Staffan Strömberg, Ph.D.

CEO since 2013. Born 1967.

M.Sc. in Chemical Engineering and Ph.D. in Organic Chemistry from the Royal Institute of Technology in Stockholm.

Staffan Strömberg has more than 20 years of experience in the pharmaceutical industry.
Besides his roles at Billerud Tenova Bioplastics and at the Swedish Medical Products Agency, he has also been Vice President of NIcOx France, had various project management positions in AstraZeneca and been Head of R&D of Swedish Orphan. Board member of Eteboxagu AB.
Former CEO of Billerud Tenova Bioplastics AB and Head of Medical Devices at the Swedish Medical Products Agency.

Shareholding in the Company: 51,873 series B-shares and 55,037 series B-shares through the wholly owned company Eteboxagu AB and 50,000 warrants 2023/2026, 50,000 warrants 2024/2027 and 65,000 employee stock options 2025/2028.

Anders Kronström

Chief Operating Officer Since 2018. Born 1967.

M.Sc., M.B.A.

Anders Kronström has over 25 years of experience working in the pharmaceutical industry. His experience spans across all stages of drug development in different disease segments. During his career at AstraZeneca he has had senior leadership positions within Project Management and Business Development.
More recently, he was a CEO of Biosergen AS, a Norwegian biotechnology company.

Shareholding in the Company: 11,194 shares of series B and 25,000 warrants 2023/2026,
25,000 warrants 2024/2027 and 32,500 employee stock options 2025/2028.

Maria Ekdahl

Chief Financial Officer since 2022. Born 1973

Master of Business Administration.

Maria has several years of financial background in both accounting and business controlling.
She has experience in various organizations such as Coca-Cola, Telenor, Karolinska Hospital and the Swedish Film Institute.

Shareholding in the company: 3,452 shares of series B and 25,000 warrants 2023/2026,
25,000 warrants 2024/2027 and 32,500 employee stock options 2025/2028.

Thomas J. Schnitzer, MD, PhD

CHIEF SCIENTIFIC OFFICER

Dr. Schnitzer is a professor at Northwestern University Feinberg School of Medicine where he founded and directed the Office of Clinical Research and held the position of assistant dean for clinical research. He has advised numerous pharmaceutical and biotechnology companies, providing guidance in the design, conduct and analysis of clinical studies of novel drugs. He is a Master of the American College of Rheumatology, served on the editorial board of numerous journals, and has published over 200 peer-reviewed publications.

Shareholding in the Company: 7,000 warrants 2024/2027.

Sanjiv Sharma, M.B.A.

Head of Medical Affairs

Sanjiv has a blend of successful executive level experience in large, mid-size and start-up companies across three continents with national and global responsibility for companies like Sanofi, Biovail (Valient) and various start-ups – NicOx and Duchesnay USA and more recently HLS Therapeutics.

Shareholding in the Company: 7,000 warrants 2024/2027.